SCHOTT Introduces Cartridge Design for High-Speed Filling
New design meets new process requirements.
At INTERPHEX last month, SCHOTT Pharmaceutical Systems introduced glass cartridges that have been developed specifically for the use on high-speed filling lines. The new design enables quicker processing and reduces overfill losses, the company said in a press release.
More companies are using high-speed filling lines to meet the growing demand for insulin products, and the trend is expected to spread to other products, such as dental cartridges. High-speed filling lines, which can fill up to 600 cartridges per minute, have special quality requirements for cartridges. SCHOTT, in partnership with lead customers, translated these process requirements into a new product design that includes defining the neck specification with respect to straightness and cosmetic defects. Manufacturing for the cartridges will be piloted in St. Gallen, Switzerland, where SCHOTT’s competence center for cartridges is based and from where modifications to manufacturing will be managed globally.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
